NCT00277511已完成3 期
Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Primary efficacy data will be determined by eradication rate based on microbiologically evaluable subjects, evaluated for each pathogen and subject.
研究概览
简要总结
Primary objective:
- To investigate the microbiological efficacy, assessed as eradication rate based on microbiologically evaluable patients 1 month post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II)
Secondary objectives:
- To investigate the microbiological efficacy, assessed as eradication rate based on microbiologically evaluable patients 6 months post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II).
- To assess the clinical response rate based on resolution of signs and symptoms after 2 weeks of treatment; 5-12 days, 1 month, 3 months and 6 months post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II).
- To assess the safety of Levofloxacin 500 mg on the basis of adverse events, standard clinical chemistry, hematology, urinalysis and vital signs in male adults with chronic bacterial prostatitis (CBP, category II).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subjects meeting all of the following criteria will be considered for enrollment into the study:
- •A clinical diagnosis of chronic prostatitis as evidenced by the following criteria:
- •clinical signs and symptoms of prostatitis and
- •a history of chronic prostatitis as defined as: symptomatic prostatitis (a clinical diagnosis of prostatitis having been made for at least one previous episode which episode having lasted four weeks or two or more other episodes during the previous twelve months) and leucocyturia greater/equal 10 WBC/HPF x 400
- •Laboratory evidence of prostatitis
- •Candidate is appropriate for oral therapy.
- •OTC medications for chronic prostatitis (other than antibiotics), which the subject has been receiving must continue throughout the study at the same dose or be discontinued prior to study entry.
排除标准
- •Subjects presenting with any of the following will not be included in the study:
- •Need for parenteral therapy for the treatment of chronic bacterial prostatitis (CBP, Category II)
- •Subjects with pathogen known or suspected to be resistant to the study drug
- •Requirement for a second systemic antibacterial regimen
- •Any condition which may interfere with the evaluation of the study drug including transurethral prostatectomy within 6 months of enrollment, the presence of a permanent transurethral catheter or a history of cystostomy or nephrostomy
- •Taking medication that may effect bladder or prostate function (e.g. hormone therapy anticholinergics or alpha-blocker)
- •Patients not receiving saw palmetto at the time of study entry should not start treatment with saw palmetto within 10 weeks of study entry
- •Known prostatic carcinoma
- •The presence of another infection requiring therapy with an antibacterial other than the study drug
- •Greater than 24 hours of potentially effective therapy within seven days prior to study when there is documented evidence of a resistant organism or clinical failure after five or more days of previous antibacterial therapy
- •History of hypersensitivity to the investigational product or to drugs with similar chemical structures
- •History of tendonitis or tendon rupture
- •Treatment with other quinolones in the last 14 days before study entry
- •Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.
- •Treatment with any investigational product in the last 30 days before study entry
- •Clinically relevant cardiovascular, hepatic, neurologic, endocrine or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
- •History of drug or alcohol abuse
- •Impaired hepatic function, as shown by:
- •AST (SGOT) greater/equal 3 times the upper limit of the reference range
- •ALT (SGPT) greater/equal 3 times the upper limit of the reference range
- •bilirubin greater 51 µmol/l, i.e., greater 3 mg/dl (except of Gilbert disease)
- •hepatic encephalopathy
- •Impaired renal function, as shown by either creatinine clearance smaller 50 ml/min or undergoing hemodialysis or peritoneal dialysis (creatinine clearance may be estimated by formula or nomogram)
- •Underweight (40 kg or less)
结局指标
主要结局
Primary efficacy data will be determined by eradication rate based on microbiologically evaluable subjects, evaluated for each pathogen and subject.
时间窗: determined at 1 month follow-up
次要结局
- Secondary efficacy data will be determined by microbiological eradication rate(at 6 months follow-up)
- clinical response rate based on resolution of signs and symptoms(after 2 weeks of treatment and during follow-up period.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum MalariaMalariaNCT00316329Sanofi1,032
已完成
不适用
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer ParticipantsLocally Advanced or Metastatic Breast CancerNCT03437083Eisai Korea Inc.340
Unknown
2 期
Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis BChronic Hepatitis BNCT01242787LG Life Sciences115
终止
不适用
Fc factOrs and Real-World hemophiliA Patient-ReporteD OutcomesHemophilia BHemophilia ANCT02392156Bioverativ Therapeutics Inc.3
已完成
2 期
Finafloxacin for the Treatment of cUTI and/or Acute PyelonephritisUrinary Tract InfectionsAcute PyelonephritisNCT01928433MerLion Pharmaceuticals GmbH225